KR102737831B1 - Cosmetic composition for improving skin wrinkles containing exosomes - Google Patents
Cosmetic composition for improving skin wrinkles containing exosomes Download PDFInfo
- Publication number
- KR102737831B1 KR102737831B1 KR1020240016510A KR20240016510A KR102737831B1 KR 102737831 B1 KR102737831 B1 KR 102737831B1 KR 1020240016510 A KR1020240016510 A KR 1020240016510A KR 20240016510 A KR20240016510 A KR 20240016510A KR 102737831 B1 KR102737831 B1 KR 102737831B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- skin
- cosmetic composition
- collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/068—Microemulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/85—Polyesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 엑소좀을 함유한 피부주름 개선용 화장료 조성물에 관한 것으로, 더욱 상세하게는 MTS공법에 적용가능하며 피부침투 효과의 향상으로 인해 우수한 피부주름 개선 효과를 나타낼 뿐만 아니라, 피부트러블을 유발하지 않고 피부진정 효과를 나타내는 엑소좀을 함유한 피부주름 개선용 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition for improving skin wrinkles containing exosomes, and more specifically, to a cosmetic composition for improving skin wrinkles containing exosomes which is applicable to an MTS method and exhibits an excellent skin wrinkle improvement effect due to an improvement in skin penetration effect, and also exhibits a skin soothing effect without causing skin trouble.
댄 벨스키 미국 듀크대 교수 연구팀은 954명을 대상으로 12년간 추적조사를 진행한 끝에 노화는 26세부터 시작되며 신체나이가 38세에 이르렀을 때 노화가 가장 빠르게 진행된다는 사실을 발견했다. 연구팀은 1972~1973년에 태어난 뉴질랜드에 사는 성인들을 대상으로 연구를 진행했다. 신체 내부를 측정하기 위해 신장, 간, 폐, 대사 및 면역기능, 콜레스테롤 수치, 심폐기능, 치아 상태 등을 지표로 사용했다. 또한 염색체의 끝 부분에서 세포분열을 조절해 노화를 결정하는 텔로미어의 길이와, 눈 뒤쪽 모세혈관의 상태를 포함해 총 18가지 항목으로 신체 나이를 측정했다. 노화가 시작되면서 피부 또한 25세 기준으로 피부 재생 세포가 감소하게 된다. 노화 뿐만 아니라 외부의 각종 유해환경 및 스트레스에 노출되어 여러 손상을 받고 있는 현대인들의 피부는 나이가 들어감에 따라 생리 활성이 저하되면서 주름, 탄력저하, 건조 등 여러 피부 노화 현상도 경험하게 된다. 평균수명이 늘어 남에 따라 이런 노화증세를 개선하기 위한 화장료의 개발에 필요성을 더욱 두게 된다. 생화학 및 분자생물학의 발전을 기반으로 하여 우리 생체 내에 존재하는 성장인자와 같은 소량의 신호물질들이 발견되었으며, 이를 기반으로 한 생체의 노화 이론이 재정립되고 있다. 또한 이 신호물질은 나이가 증가함에 따라 생체 내에서 감소하게 되는데 이는 콜라겐, 엘라스틴, 히알루론산의 감소가 우리 노화와 밀접한 관련이 있다는 것을 밝히고 있다. 나이가 들어감에 따라 이 세 가지 성분이 감소하게 되면서 피부탄력 감소, 피부주름, 색소침착 등 피부노화현상이 나타나게 된다. 피부표피와 진피에서 나타나는 현상인 콜라겐의 파괴, 콜라겐 합성의 감소, 엘라스틴의 소실 및 피부생리 저하에 따른 멜라닌 색소침착 등에 의한 현상 등을 개선하기 위하여 다양한 화장료가 개발되어 지고 있다.Professor Dan Belsky's research team at Duke University in the United States conducted a 12-year follow-up study of 954 people and discovered that aging begins at age 26 and progresses most rapidly when the body age reaches 38. The research team conducted the study on adults living in New Zealand who were born between 1972 and 1973. In order to measure the inside of the body, they used indicators such as kidneys, liver, lungs, metabolic and immune functions, cholesterol levels, cardiopulmonary functions, and dental conditions. They also measured body age using 18 items in total, including the length of telomeres, which control cell division at the end of chromosomes and determine aging, and the condition of capillaries behind the eyes. As aging begins, skin regeneration cells also decrease at the age of 25. In addition to aging, the skin of modern people, which is exposed to various external harmful environments and stress and suffers various damages, experiences wrinkles, loss of elasticity, dryness, and other skin aging symptoms as physiological activity decreases with age. As the average life expectancy increases, the need for cosmetics to improve these aging symptoms has become greater. Based on the development of biochemistry and molecular biology, small amounts of signaling substances such as growth factors that exist in our bodies have been discovered, and the theory of aging in our bodies is being reestablished based on this. In addition, these signaling substances decrease in our bodies as we age, and this shows that the decrease in collagen, elastin, and hyaluronic acid is closely related to our aging. As these three components decrease with age, skin aging phenomena such as decreased skin elasticity, wrinkles, and pigmentation appear. Various cosmetics are being developed to improve phenomena such as collagen destruction, decreased collagen synthesis, loss of elastin, and melanin pigmentation due to decreased skin physiology, which occur in the skin epidermis and dermis.
인체를 구성하고 있는 기관 중 가장 큰 기관인 피부는 면적 18m2, 두께 2~4mm, 무게 3kg으로 여러 개의 상이한 층들로 구성되고, 각 층은 특화된 기능을 갖으며 주요한 층들은 표피층(epidermis), 진피층(dermis) 등으로 구성되어 있다. 표피층은 가장 피부 겉면으로 각질층, 투명층, 과립층, 유극층, 기저층 총 5가지로 나뉘고 있다.The skin, the largest organ in the human body, has an area of 18 m2, a thickness of 2 to 4 mm, and a weight of 3 kg. It is composed of several different layers, each with a specialized function, and the main layers are the epidermis and dermis. The epidermis is the outermost layer of the skin and is divided into five layers: the stratum corneum, the stratum lucidum, the stratum granulosum, the stratum spinosum, and the stratum basale.
표피층에 있는 투명층과 과립층 사이에는 수분저지막이 있는데, 이는 화학적 성질을 지난 특수막으로 외부로부터 이물질의 침투를 막고 피부내부로부터의 수분이 날아가는 것을 막아주는 역할을 하고 있다. 이 수분저지막으로 인해 이물질 뿐만 아니라 물도 내부로 침입할 수 없는데, 이로인해 화장품의 유효성분 또한 피부 깊숙이 침투가 어려워 지게 된다. 진피층은 피부조직의 90% 이상을 차지하고 있어서 피부모양을 결정짓는 진짜 피부라고도 하여 진피라고 불리는데 진피층은 유두층과 망상층으로 나뉘고 있다. 유두층 아래한 망상층은 단단하고 불규칙적인 그물모양을 결합조직으로 진피층의 대부분을 차지하고 있는데, 콜라겐, 엘라스틴, 히알루론산등으로 구성되어 있다.Between the transparent layer and the granular layer in the epidermis is a moisture barrier, which is a special chemical barrier that prevents the penetration of foreign substances from the outside and prevents moisture from escaping from the inside of the skin. Due to this moisture barrier, not only foreign substances but also water cannot penetrate inside, which makes it difficult for the effective ingredients of cosmetics to penetrate deep into the skin. The dermis layer accounts for more than 90% of the skin tissue, so it is called the dermis because it is the real skin that determines the shape of the skin. The dermis layer is divided into the papillary layer and the reticular layer. The reticular layer, located below the papillary layer, is a hard, irregular mesh-shaped connective tissue that makes up most of the dermis and is composed of collagen, elastin, hyaluronic acid, etc.
한편, 물리적 경피 흡수방법인 MTS(Microneedle Therapy System)는 인체의 안정성과 효용성이 확립되어 있는 미세침으로, 화장품 제형의 흡수를 촉진하는데 효과적인 방법으로 사료되는 것이 입증되어 있다. 0.25mm~0.5mm의 아주 미세한 계획적인 통로를 물리적으로 만들어 유효성분의 흡수율을 80%이상 끌어올리기 위한 기기이다. 아무리 저분자의 화장품이라고 해도 단순 도포시에는 흡수율은 10%가 넘기기 어려운 일이기에 물리적으로 미세틈을 만들어 흡수율을 높이도록 한다. 가정용 니들로 안정성을 입증했다고 하여도 미세침으로 인한 상처가 발생할 수 있다.Meanwhile, the MTS (Microneedle Therapy System), a physical percutaneous absorption method, is a microneedle with established safety and effectiveness in the human body, and has been proven to be an effective method for promoting the absorption of cosmetic formulations. It is a device that physically creates a very fine planned passage of 0.25 mm to 0.5 mm to increase the absorption rate of effective ingredients by more than 80%. Even if it is a low-molecular cosmetic, it is difficult to exceed 10% in simple application, so micro-gaps are physically created to increase the absorption rate. Even if it is proven to be safe with home-use needles, wounds may occur due to micro-needles.
생화학 및 분자생물학의 발전을 기반으로 하여 우리 생체 내에 존재하는 성장인자와 같은 소량의 신호물질들이 발견되었으며, 이를 기반으로 한 생체의 노화 이론이 재정립되고 있다. 또한 이 신호물질은 나이가 증가함에 따라 생체 내에서 감소하게 되는데 바로 콜라겐, 히알루론산, 엘라스틴의 감소가 우리의 노화와 밀접한 관계가 있다는 것이 밝혀지고 있다. 콜라겐은 아미노산이 모여 구성된 단백질의 일종으로 세포나 조직을 접착제처럼 결합시켜 세포 활동의 발판 역할을 하며, 체내 세포와 세포 사이에 존재하여 모든 세포를 연결하는 역할을 한다.Based on the development of biochemistry and molecular biology, small amounts of signaling substances such as growth factors that exist in our bodies have been discovered, and the theory of aging in the body is being reestablished based on this. In addition, these signaling substances decrease in the body as we age, and it has been revealed that the decrease in collagen, hyaluronic acid, and elastin is closely related to our aging. Collagen is a type of protein composed of amino acids, and it acts as a foundation for cell activity by binding cells and tissues like glue, and exists between cells in the body to connect all cells.
엘라스틴은 스프링 모양의 경단백질이며, 콜라겐 사이에 존재하며 결혼 조직으로 얽혀 있다. 스프링 구조로 되어있기 때문에, 엘라스틴 함량이 줄면 구조가 느슨해져 피부가 쉽게 쳐지고 잔주름이 생길 가능성이 높다. 히알루론산은 눈의 소자체, 닭의 벼슬, 관절액 등 동물의 결합조직에 널리 존재하고 있는 산성 뮤코다당류의 일종으로 N-아세틸-D-글루코사민과 D-글루큐론산을 반복구성단위로 하는 고분자 물질이다. 타 뮤코다당류에 비해 분자량이 크고 매우 높은 수분 흡수력을 가지고 있다. 1g의 히알루론산은 수중에서 약 1L의 체적을 차지한다는 보고가 있다. 피부는 노화가 진행되기 전에는 피부세포의 생리활성이 활발하다. 진피에 있는 섬유아세포에서는 콜라겐의 합성과 신진대사가 왕성하며 히알루론산, 엘라스틴을 포함한 당단백질류인 GAGS합성도 활발하여 피부에 탄력성, 부드러움, 유연성 및 보습성을 부여한다. 그러나 현대인의 피부는 외부의 각종 유해 환경 및 스트레스에 노출되어 다양한 손상을 받고 있고, 나이가 들면서 피부의 생리활성이 저하되고 손상된 피부의 회복속도가 느려지면서 피부는 탄력 저하, 건조, 주름 형성, 색소침착, 검버섯, 칙칙함 등의 다양한 피부 노화 현상이 나타난다. 이러한 피부의 문제를 해결하기 위해 해당 원료들을 포함하는 화장료 조성물이 필요할 수 있다.Elastin is a spring-shaped light protein that exists between collagen and is entangled in a marriage tissue. Because it has a spring structure, if the elastin content decreases, the structure becomes loose, making it easy for the skin to sag and wrinkles to form. Hyaluronic acid is a type of acidic mucopolysaccharide that is widely present in the connective tissue of animals such as eye cells, chicken combs, and synovial fluid, and is a high molecular weight substance with N-acetyl-D-glucosamine and D-glucuronic acid as repeating units. It has a large molecular weight and very high water absorption capacity compared to other mucopolysaccharides. It is reported that 1 g of hyaluronic acid occupies a volume of about 1 L in water. Before skin aging, the physiological activity of skin cells is active. In the fibroblasts in the dermis, collagen synthesis and metabolism are active, and the synthesis of glycoproteins including hyaluronic acid and elastin, GAGS, is also active, giving the skin elasticity, softness, flexibility, and moisture. However, the skin of modern people is exposed to various external harmful environments and stresses, and is damaged in various ways, and as they age, the physiological activity of the skin decreases and the recovery speed of damaged skin slows down, causing various skin aging phenomena such as loss of elasticity, dryness, wrinkle formation, pigmentation, liver spots, and dullness. To solve these skin problems, a cosmetic composition containing the relevant raw materials may be required.
또한, 리포좀은 현재 제약 분야 뿐 만 아니라 화장품, 식품 등에도 널리 이용되는 있는데 이는 생리활성 성분을 안정하게 전달할 수 있다는 장점을 갖고 있다. 정맥주사, 척수주사와 같은 주사로 쓰이기도 하고 상처가 났을 때 바르는 연고로 사용되기도 한다. 이는 연고안에 유효한 성분들이 피부 겉표면인 표피가 아닌 진피 안에 침투되도록 하여 피부 재생을 촉진시키기 위함인데, 이같은 성질은 화장품분야에서도 사용이 되어 지고 있다. 화장품에서 리포좀의 유용성은 소수성(Hydrophobic)인 피부에 대해 흡수 및 친화성이 작은 수용성(Water-soluble) 유효성분을 인지질로 된 리포좀 내에 포접하는 것으로 표피층의 수분저지막을 통과 하면서 피부흡수의 문제를 개선할 수 있는 특성을 가지고 있다. 리포좀은 크게 다막리포좀(MLV:Multilamella vesicle)과 단막리포좀(ULV:Unilamella vesicle)로 구분되고 ULV는 다사 대단막리포좀(Large Unilamella vesicle)과 소단막리포좀(Small Unilamella vesicle)으로 나눌 수 있다. MLV는 그 크기가 500~5,500nm(나노미터)이고 리포좀 안에 내포시킬 수 있는 량은 5~15%이고, LUV는 그 크기가 200~800nm 이고 리포 좀 안에 내포시킬 수 있는 량은 36~65%이고, SUV는 크기는 20~150nm이며, 리포좀 안에 내포시킬 수 있는 량은 0.5~1.0%이다. 생리활성 물질을 내포시킬 수 있는 양은 LUV가 가장 많으나 불안정하고, 사람의 피부 의 구조는 다막(Multilamella)의 구조를 갖고 있어 MLV는 피부와 친화력이 있으나 크기가 너무 커 피부 침투가 어렵다. 그래서 화장품에서 사용되는 리포좀 입자는 피부내 전달에 있어서 안정성과 유효성을 가져야 하기 때 문에 SUV형태일 때 더 높은 것으로 사료된다. 더불어 콜라겐, 엘라스틴, 히 알루 론산과 같이 피부층보다 큰 고분자물질을 리포좀 공법을 통하여 분 자량을 쪼개어 침투율을 높일 수 있다. 입자크기를 최소한 친수성 물질로, 피부와 유사한인지질로 되어 피부 깊숙이 유효성분들을 전달 하도록 한다.In addition, liposomes are widely used not only in the pharmaceutical field but also in cosmetics and food because they have the advantage of being able to stably deliver physiologically active ingredients. They are used as injections such as intravenous injections and spinal injections, and are also used as ointments applied to wounds. This is to promote skin regeneration by allowing the effective ingredients in the ointment to penetrate into the dermis rather than the epidermis, which is the outer surface of the skin. This property is also being used in the cosmetics field. The usefulness of liposomes in cosmetics is that they encapsulate water-soluble active ingredients with low absorption and affinity for hydrophobic skin into liposomes made of phospholipids, and they have the property of improving the problem of skin absorption while passing through the moisture barrier of the epidermis. Liposomes are largely divided into multilamellar vesicles (MLV) and unilamellar vesicles (ULV). ULV can be divided into large unilamellar vesicles and small unilamellar vesicles. MLV is 500–5,500 nm (nanometers) in size and the amount that can be incorporated into liposomes is 5–15%, LUV is 200–800 nm in size and the amount that can be incorporated into liposomes is 36–65%, and SUV is 20–150 nm in size and the amount that can be incorporated into liposomes is 0.5–1.0%. LUV can contain the largest amount of physiologically active substances, but it is unstable, and the structure of human skin is a multilamellar structure, so MLV has an affinity for the skin, but its size is too large to penetrate the skin. Therefore, liposome particles used in cosmetics must have stability and effectiveness for delivery into the skin, so it is thought that it is higher when it is in the SUV form. In addition, the penetration rate can be increased by splitting the molecular weight of high molecular substances larger than the skin layer, such as collagen, elastin, and hyaluronic acid, through the liposome method. The particle size should be at least hydrophilic and a phospholipid similar to the skin to deliver the active ingredients deep into the skin.
본 발명의 목적은 MTS공법에 적용가능하며 피부침투 효과의 향상으로 인해 우수한 피부주름 개선 효과를 나타낼 뿐만 아니라, 피부트러블을 유발하지 않고 피부진정 효과를 나타내는 엑소좀을 함유한 피부주름 개선용 화장료 조성물을 제공하는 것이다.The purpose of the present invention is to provide a cosmetic composition for improving wrinkles in the skin, containing exosomes, which is applicable to the MTS method and exhibits an excellent wrinkle improvement effect due to improved skin penetration effect, as well as a skin soothing effect without causing skin trouble.
본 발명의 목적은 유효성분 100 중량부 및 엑소좀이 함유된 폴리머좀 0.1 내지 10 중량부로 이루어지며, 상기 유효성분은 소듐하이알루로네이트, 콜라겐 및 하이드롤라이즈드엘라스틴이 함유되고, 상기 소듐하이알루로네이트, 콜라겐 및 하이드롤라이즈드엘라스틴은 120 내지 200 나노미터로 에멀전화되는 것을 특징으로 하는 엑소좀을 함유한 피부주름 개선용 화장료 조성물을 제공함에 의해 달성된다.The object of the present invention is achieved by providing a cosmetic composition for improving skin wrinkles containing exosomes, comprising 100 parts by weight of an effective ingredient and 0.1 to 10 parts by weight of polymersomes containing exosomes, wherein the effective ingredients contain sodium hyaluronate, collagen and hydrolyzed elastin, and the sodium hyaluronate, collagen and hydrolyzed elastin are emulsified to a size of 120 to 200 nanometers.
본 발명의 바람직한 특징에 따르면, 상기 유효성분은 글리세린, 정제수, 카프릴릭/카프릭트라이글리세라이드, 병풀추출물, 하이드로제네이티드레시틴, 콜레스테롤, 소듐하이알루로네이트, 콜라겐, 하이드롤라이즈드엘라스틴, 폴리락틱애씨드 및 인체유래 줄기세포 배양액으로 이루어지는 것으로 한다.According to a preferred feature of the present invention, the effective ingredients are composed of glycerin, purified water, caprylic/capric triglyceride, centella asiatica extract, hydrogenated lecithin, cholesterol, sodium hyaluronate, collagen, hydrolyzed elastin, polylactic acid, and human-derived stem cell culture solution.
본 발명의 더 바람직한 특징에 따르면, 상기 유효성분은 글리세린 100 중량부, 정제수 18 내지 22 중량부, 카프릴릭/카프릭트라이글리세라이드 7 내지 9 중량부, 병풀추출물 2.5 내지 3 중량부, 하이드로제네이티드레시틴 2.5 내지 3 중량부, 콜레스테롤 0.5 내지 1.0 중량부, 소듐하이알루로네이트 0.1 내지 0.15 중량부, 콜라겐 0.1 내지 0.15 중량부, 하이드롤라이즈드엘라스틴 0.1 내지 0.15 중량부, 폴리락틱애씨드 0.1 내지 0.15 중량부 및 인체유래 줄기세포 배양액 0.01 내지 0.02 중량부로 이루어지는 것으로 한다.According to a more preferred feature of the present invention, the effective ingredient comprises 100 parts by weight of glycerin, 18 to 22 parts by weight of purified water, 7 to 9 parts by weight of caprylic/capric triglyceride, 2.5 to 3 parts by weight of centella asiatica extract, 2.5 to 3 parts by weight of hydrogenated lecithin, 0.5 to 1.0 parts by weight of cholesterol, 0.1 to 0.15 parts by weight of sodium hyaluronate, 0.1 to 0.15 parts by weight of collagen, 0.1 to 0.15 parts by weight of hydrolyzed elastin, 0.1 to 0.15 parts by weight of polylactic acid, and 0.01 to 0.02 parts by weight of a human-derived stem cell culture solution.
본 발명의 더욱 바람직한 특징에 따르면, 상기 병풀 추출물은 병풀 100 중량부에 탄소수가 1 내지 4인 저급알코올 200 내지 1000 중량부를 혼합하고 추출하여 제조되는 것으로 한다.According to a more preferred feature of the present invention, the purslane extract is prepared by mixing 200 to 1,000 parts by weight of a lower alcohol having 1 to 4 carbon atoms with 100 parts by weight of purslane and extracting the mixture.
본 발명의 더욱 더 바람직한 특징에 따르면, 상기 엑소좀을 함유한 피부주름 개선용 화장료 조성물은 화장수, 아이크림, 수분크림, 클렌징제품, 세럼 및 앰플로 이루어진 그룹에서 선택된 하나의 제형으로 적용되는 것으로 한다.According to a further preferred feature of the present invention, the cosmetic composition for improving skin wrinkles containing the exosome is applied in one formulation selected from the group consisting of a toner, an eye cream, a moisturizing cream, a cleansing product, a serum, and an ampoule.
본 발명에 따른 엑소좀을 함유한 피부주름 개선용 화장료 조성물은 MTS공법에 적용가능하며 피부침투 효과의 향상으로 인해 우수한 피부주름 개선 효과를 나타낼 뿐만 아니라, 피부트러블을 유발하지 않고 피부진정 효과를 나타내는 화장료 조성물을 제공하는 탁월한 효과를 나타낸다.The cosmetic composition for improving wrinkles in the skin containing exosomes according to the present invention is applicable to the MTS method and not only exhibits an excellent wrinkle improvement effect due to the improvement of skin penetration effect, but also exhibits an excellent effect of providing a cosmetic composition that exhibits a skin soothing effect without causing skin trouble.
이하에는, 본 발명의 바람직한 실시예와 각 성분의 물성을 상세하게 설명하되, 이는 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 발명을 용이하게 실시할 수 있을 정도로 상세하게 설명하기 위한 것이지, 이로 인해 본 발명의 기술적인 사상 및 범주가 한정되는 것을 의미하지는 않는다.Hereinafter, preferred embodiments of the present invention and the properties of each component will be described in detail. However, this is intended to be a detailed description to enable a person having ordinary skill in the art to which the present invention pertains to easily carry out the invention, and does not mean that the technical idea and scope of the present invention are limited thereby.
본 발명에 따른 엑소좀을 함유한 피부주름 개선용 화장료 조성물은 유효성분에 엑소좀이 함유된 폴리머좀으로 이루어지며, 유효성분 100 중량부에 엑소좀(Exosome)이 함유된 폴리머좀 0.1 내지 10 중량부로 이루어지는 것이 바람지하다.The cosmetic composition for improving skin wrinkles containing exosomes according to the present invention is composed of polymersomes containing exosomes in the active ingredient, and is preferably composed of 0.1 to 10 parts by weight of polymersomes containing exosomes per 100 parts by weight of the active ingredient.
상기 유효성분은 소듐하이알루로네이트, 콜라겐 및 하이드롤라이즈드엘라스틴이 함유되는데, 상기의 성분이 함유된 유효성분은 우수한 피부노화 방지 및 주름개선 효과를 나타낸다.The above effective ingredients include sodium hyaluronate, collagen, and hydrolyzed elastin, and the effective ingredients containing the above ingredients exhibit excellent skin anti-aging and wrinkle improvement effects.
또한, 상기 소듐하이알루로네이트, 콜라겐 및 하이드롤라이즈드엘라스틴은 나이가 들수록 감소하는 진피층에서 감소하는 소듐하이알루로네이트, 콜라겐 및 하이드롤라이즈드엘라스틴 성분을 보충해 피부노화나 주름방지효과를 부여하는 역할을 한다.In addition, the sodium hyaluronate, collagen and hydrolyzed elastin above serve to supplement the sodium hyaluronate, collagen and hydrolyzed elastin components that decrease in the dermis layer, which decreases with age, thereby providing an anti-aging and wrinkle-prevention effect on the skin.
또한, 상기의 소듐하이알루로네이트, 콜라겐 및 하이드롤라이즈드엘라스틴이 피부 깊이 침투할 수 있도록 리포좀 공법을 통해 리포좀화하는 것이 바람직하며, 이때, 상기와 같이 엑소좀이 함유된 폴리머좀을 혼합하여 리포좀화하는 것이 바람직하다.In addition, it is preferable to liposomeize the above-mentioned sodium hyaluronate, collagen, and hydrolyzed elastin through liposome method so that they can penetrate deep into the skin. At this time, it is preferable to liposomeize them by mixing polymersomes containing exosomes as described above.
또한, 상기의 소듐하이알루로네이트, 콜라겐 및 하이드롤라이즈드엘라스틴은 75 내지 80℃의 온도로 가열된 상태에서 고압균질기로 교반한 후에 40℃로 냉각하고, 마이크로에멀전화기기(Microfluidizer, MFD)를 이용하여 평균입자가 120 내지 200 나노미터를 나타내도록 한 후에 에멀전화되는 것이 바람직하다.In addition, it is preferable that the above sodium hyaluronate, collagen and hydrolyzed elastin are stirred in a high-pressure homogenizer while heated to a temperature of 75 to 80°C, cooled to 40°C, and emulsified using a microfluidizer (MFD) so that the average particle size is 120 to 200 nanometers.
상기와 같이 마이크로에멀전화기기를 이용하여 7 내지 10회 처리하게 되면 평균입자가 약 120 내지 150 나노미터를 나타내게 되며, 마이크로에멀전화기기를 이용하여 10 내지 20회 처리하게 되면 150 내지 200 나노미터의 평균입자 크기를 나타내게 된다.As described above, if the microemulsion device is used for processing 7 to 10 times, the average particle size will be approximately 120 to 150 nanometers, and if the microemulsion device is used for processing 10 to 20 times, the average particle size will be 150 to 200 nanometers.
상기와 같은 평균입자크기를 나타내는 소듐하이알루로네이트, 콜라겐 및 하이드롤라이즈드엘라스틴은 피부침투 효과가 월등하게 향상된다.Sodium hyaluronate, collagen and hydrolyzed elastin exhibiting the above-mentioned average particle size have significantly improved skin penetration effects.
이때, 상기 유효성분은 글리세린, 정제수, 카프릴릭/카프릭트라이글리세라이드, 병풀추출물, 하이드로제네이티드레시틴, 콜레스테롤, 소듐하이알루로네이트, 콜라겐, 하이드롤라이즈드엘라스틴, 폴리락틱애씨드 및 인체유래 줄기세포 배양액으로 이루어지는 것이 바람직하며, 상기 유효성분은 글리세린 100 중량부, 정제수 18 내지 22 중량부, 카프릴릭/카프릭트라이글리세라이드 7 내지 9 중량부, 병풀추출물 2.5 내지 3 중량부, 하이드로제네이티드레시틴 2.5 내지 3 중량부, 콜레스테롤 0.5 내지 1.0 중량부, 소듐하이알루로네이트 0.1 내지 0.15 중량부, 콜라겐 0.1 내지 0.15 중량부, 하이드롤라이즈드엘라스틴 0.1 내지 0.15 중량부, 폴리락틱애씨드 0.1 내지 0.15 중량부 및 인체유래 줄기세포 배양액 0.01 내지 0.02 중량부로 이루어지는 것이 더욱 바람직하다.At this time, it is preferable that the effective ingredients are composed of glycerin, purified water, caprylic/capric triglyceride, centella asiatica extract, hydrogenated lecithin, cholesterol, sodium hyaluronate, collagen, hydrolyzed elastin, polylactic acid, and human-derived stem cell culture solution, and the effective ingredients are 100 parts by weight of glycerin, 18 to 22 parts by weight of purified water, 7 to 9 parts by weight of caprylic/capric triglyceride, 2.5 to 3 parts by weight of centella asiatica extract, 2.5 to 3 parts by weight of hydrogenated lecithin, 0.5 to 1.0 parts by weight of cholesterol, 0.1 to 0.15 parts by weight of sodium hyaluronate, 0.1 to 0.15 parts by weight of collagen, 0.1 to 0.15 parts by weight of hydrolyzed elastin, It is more preferable that the composition comprises 0.1 to 0.15 parts by weight of polylactic acid and 0.01 to 0.02 parts by weight of a human-derived stem cell culture medium.
상기 글리세린 100 중량부 대비 소듐하이알루로네이트의 함량이 0.1 중량부 미만이면 노화방지효과가 저하되며, 상기 소듐하이알루로네이트의 함량이 0.15 중량부를 초과하게 되면 본 발명을 통해 제조되는 피부주름 개선용 화장료 조성물의 점도가 지나치게 증가하여 MTS공법에 적용이 어려워진다.If the content of sodium hyaluronate is less than 0.1 part by weight relative to 100 parts by weight of the above glycerin, the anti-aging effect is reduced, and if the content of sodium hyaluronate exceeds 0.15 parts by weight, the viscosity of the cosmetic composition for improving wrinkles manufactured through the present invention excessively increases, making it difficult to apply it to the MTS method.
또한, 병풀 추출물은 0.1 내지 5 중량부가 함유되는데, 상처치유 및 피부재생 효과가 우수하며, 염증개선, 피부진정 및 소염 작용 등의 효과를 나타내어 피부 트러블을 개선하는 효과를 부여하는 역할을 한다.In addition, the extract of the purslane is contained in an amount of 0.1 to 5 parts by weight, and has excellent wound healing and skin regeneration effects, and has effects such as improving inflammation, soothing the skin, and anti-inflammatory effects, thereby playing a role in improving skin troubles.
이때, 상기 병풀추출물은 병풀 100 중량부에 탄소수가 1 내지 4인 저급알코올 200 내지 1000 중량부를 혼합하고 추출하여 제조되는데, 상기의 과정을 통해 제조되는 병풀 추출물은 상기의 효과 외에도 NO 활성 억제, 히스타민 분비 감소, RANTES의 함량 감소, 콜라게나아제의 활성 감소 및 MMP-1 발현량 감소 등의 효과를 나타내어 항염, 항주름, 항알러지 등의 효과를 부여하여 우수한 피부 탄력도 개선 및 피부 주름 개선 효과를 나타낸다.At this time, the above-mentioned purslane extract is prepared by mixing 200 to 1,000 parts by weight of lower alcohol having 1 to 4 carbon atoms with 100 parts by weight of purslane and extracting it. The purslane extract prepared through the above process, in addition to the above-mentioned effects, exhibits effects such as inhibition of NO activity, reduction of histamine secretion, reduction of RANTES content, reduction of collagenase activity, and reduction of MMP-1 expression level, thereby imparting anti-inflammation, anti-wrinkle, anti-allergy, etc. effects and exhibiting excellent skin elasticity improvement and skin wrinkle improvement effects.
상기 병풀 추출물의 함량이 0.1 중량부 미만이면 상기의 효과가 미미하며, 상기 병풀 추출물의 함량이 5 중량부를 초과하게 되면 상기의 효과는 크게 향상되지 않으면서 화장료 조성물의 제형안정성이 저하될 수 있기 때문에 바람직하지 못하다.If the content of the above-mentioned purslane extract is less than 0.1 parts by weight, the above-mentioned effect is minimal, and if the content of the above-mentioned purslane extract exceeds 5 parts by weight, the above-mentioned effect is not significantly improved, but the formulation stability of the cosmetic composition may be reduced, which is not preferable.
상기 인체유래 줄기세포 배양액은 배아줄기세포를 제외한 성체로부터 얻어지는 줄기세포를 의미하며, 예로서 지방, 골수, 제대혈 및 말초혈액을 포함하는 혈액 및 조직의 기저에서 기원되는 줄기세포를 모두 포함하나 이에 한정되지는 않는다.The above human-derived stem cell culture medium refers to stem cells obtained from adults, excluding embryonic stem cells, and includes, but is not limited to, stem cells originating from the base of blood and tissues, including fat, bone marrow, umbilical cord blood, and peripheral blood.
화장품 분야에서의 인체유래 줄기세포의 이용은 그 대사산물로서의 성장인자를 이용하며, 성장인자들은 세포의 표면에 있는 수용체와 결합하여 세포의 증식과 분화를 자극하는 작용을 하는 단백질로서 EGF(표피세포성장인자), TGF(형질전환성장인자), HGF(간세포증식 인자), FGF (섬유아세포성장인자), IGF(인슐린유사성장인자), SOD(항산화효소), 콜라겐, 파이브로넥틴 등이 포함된다.The use of human-derived stem cells in the cosmetics field utilizes growth factors as their metabolites. Growth factors are proteins that stimulate cell proliferation and differentiation by binding to receptors on the surface of cells, and include EGF (epidermal growth factor), TGF (transforming growth factor), HGF (hepatocyte proliferation factor), FGF (fibroblast growth factor), IGF (insulin-like growth factor), SOD (antioxidant enzyme), collagen, and fibronectin.
상기 엑소좀이 함유된 폴리머좀은 0.1 내지 10 중량부가 함유되며, 엑소좀과 폴리에틸렌글리콜이 5:2로 혼합된 혼합물에 팔미토일트리펩타이드를 첨가하여 제조되는데, 지질과 유사한 생체적합, 생분해성 고분자의 자기회합에 의한 분자 이중층 베지클로 펩타이드와 폴리머좀의 박막과 흡착하지 않아 내부의 펩타이드와 같은 효능 물질 뿐만 아니라, 상기 유효성분의 변성을 근본적으로 차단하여 고유 활성을 온전히 유지시켜 줄 수 있는 장점을 나타낸다.The polymersome containing the exosome is contained in an amount of 0.1 to 10 parts by weight, and is manufactured by adding palmitoyl tripeptide to a mixture of exosomes and polyethylene glycol in a ratio of 5:2, and exhibits an advantage in that the polymersome does not adsorb to the molecular bilayer vesiculopeptide and the thin film of the polymersome through self-association of biocompatible and biodegradable polymers similar to lipids, thereby fundamentally blocking denaturation of the effective ingredient as well as the effective substance such as the peptide inside, thereby completely maintaining the inherent activity.
상기 폴리머좀은 입자 직경이 300 내지 1000 나노미터를 나타내며, 피부 흡수가 가능한 크기로 합성되는데, 상기 팔미토일트리펩타이드는 폴리머좀 총 중량에 대하여 0.0001∼1 중량%로 함유되는 것이 바람직한데, 상기의 성분으로 이루어지는 폴리머좀은 상기 유효성분의 피부침투 효과를 향상시킬 뿐만 아니라, 폴리머좀 자체에 팔미토일트리펩타이드 성분이 함유되어 피부노화 방지효과를 더욱 향상시킬 수 있다.The above polymersomes have a particle diameter of 300 to 1000 nanometers and are synthesized in a size that can be absorbed by the skin. The palmitoyl tripeptide is preferably contained in an amount of 0.0001 to 1 wt% based on the total weight of the polymersomes. The polymersomes composed of the above components not only enhance the skin penetration effect of the effective ingredient, but also further enhance the skin aging prevention effect because the polymersomes themselves contain the palmitoyl tripeptide component.
상기 폴리머좀의 함량이 0.1 중량부 미만이면 상기의 효과가 미미하며, 상기 폴리머좀의 함량이 10 중량부를 초과하게 되면 상대적으로 유효성분의 함량이 지나치게 줄어들어 피부주름개선 효과가 저하될 뿐만 아니라, 화장료 조성물의 점도가 지니치게 증거하여 MTS공법에 적용이 어려울 수 있다.If the content of the above polymersome is less than 0.1 parts by weight, the above effect is minimal, and if the content of the above polymersome exceeds 10 parts by weight, the content of the effective ingredient is relatively excessively reduced, so not only is the effect of improving skin wrinkles reduced, but also the viscosity of the cosmetic composition becomes excessively high, making it difficult to apply it to the MTS method.
상기의 성분으로 이루어지는 피부주름 개선용 화장료 조성물은 그 제형이 특별히 한정되지 않지만, 피부주름 개선효과를 위해 사용빈도수나 피부에 적용되는 부분을 고려했을 때, 화장수, 아이크림, 수분크림, 클렌징제품, 세럼 및 앰플로 이루어진 그룹에서 선택된 하나의 제형으로 적용되는 것이 바람직하다.The cosmetic composition for improving skin wrinkles, comprising the above ingredients, is not particularly limited in its formulation, but considering the frequency of use or the area to which it is applied on the skin for the effect of improving skin wrinkles, it is preferable to apply it in one formulation selected from the group consisting of toner, eye cream, moisturizing cream, cleansing product, serum, and ampoule.
이하에서는, 본 발명에 따른 엑소좀을 함유한 피부주름 개선용 화장료 조성물의 제조방법 및 그 제조방법으로 제조된 화장료 조성물의 물성을 실시예를 들어 설명하기로 한다.Hereinafter, a method for manufacturing a cosmetic composition for improving skin wrinkles containing exosomes according to the present invention and the properties of a cosmetic composition manufactured by the method will be described with examples.
<제조예 1><Manufacturing Example 1>
소듐하이알루로네이트, 콜라겐 및 하이드롤라이즈드엘라스틴 각각을 78℃의 온도로 가열한 상태에서 고압균질기로 교반한 후에 40℃로 냉각하고, 마이크로에멀전화기기(Microfluidizer, MFD)를 이용하여 평균입자가 120 내지 200 나노미터를 나타내도록 하였다.Sodium hyaluronate, collagen, and hydrolyzed elastin were each heated to 78°C, stirred in a high-pressure homogenizer, cooled to 40°C, and used as a microemulsifier (Microfluidizer, MFD) to have an average particle size of 120 to 200 nanometers.
<제조예 2> 병풀 추출물의 제조<Manufacturing Example 2> Manufacturing of a bottle gourd extract
병풀 100 중량부에 질량농도가 50%인 에탄올 800 중량부를 혼합하고 전자레인지에 투입하고 90W에서 5분 동안 가열하여 병풀 추출물을 제조하였다.A centella asiatica extract was prepared by mixing 100 parts by weight of centella asiatica and 800 parts by weight of ethanol having a mass concentration of 50%, placing the mixture in a microwave oven, and heating it at 90 W for 5 minutes.
<제조예 3> 유효성분의 제조<Manufacturing Example 3> Manufacturing of effective ingredients
글리세린 73.99g, 정제수 15mL, 카프릴릭/카프릭트라이글리세라이드 6g, 하이드로제네이티드레시틴 2g, 콜레스테롤 0.6g, 상기 제조예 1을 통해 제조된 소듐하이알루로네이트 0.1g, 콜라겐 0.1g 및 하이드롤라이즈드엘라스틴 0.1g, 상기 제조예 2를 통해 제조된 병풀 추출물 2g, 폴리락틱애씨드 0.1g 및 인체유래 줄기세포 배양액(EGF, 표피세포성장인자) 0.01g을 혼합하여 유효성분을 제조하였다.An effective ingredient was prepared by mixing 73.99 g of glycerin, 15 mL of purified water, 6 g of caprylic/capric triglyceride, 2 g of hydrogenated lecithin, 0.6 g of cholesterol, 0.1 g of sodium hyaluronate, 0.1 g of collagen, and 0.1 g of hydrolyzed elastin prepared through the above Manufacturing Example 1, 2 g of the centella asiatica extract prepared through the above Manufacturing Example 2, 0.1 g of polylactic acid, and 0.01 g of human-derived stem cell culture medium (EGF, epidermal growth factor).
<제조예 4> 엑소좀이 함유된 폴리머좀의 제조<Manufacturing Example 4> Manufacturing of polymersomes containing exosomes
클로로포름에 엑소좀과 폴리에틸렌글리콜을 5:2 중량비로 혼합하여 용해한 후 반응물의 전체 중량에 대하여 1 중량%의 팔미토일트리펩타이드-5를 첨가한 후에, 마이크로플루딕스 기술을 통해 폴리머좀을 합성한 후 클로로포름을 제거하고 경화시켜 엑소좀이 함유된 폴리머좀을 제조하였다.After dissolving exosomes and polyethylene glycol in a 5:2 weight ratio in chloroform, 1 wt% of palmitoyl tripeptide-5 was added based on the total weight of the reaction mixture, and polymersomes were synthesized using microfluidics technology. After removing the chloroform and curing, polymersomes containing exosomes were manufactured.
<실시예 1><Example 1>
상기 제조예 3을 통해 제조된 유효성분 100 중량부에 상기 제조예 4를 통해 제조된 엑소좀이 함유된 폴리머좀 5 중량부를 혼합하고 150rpm의 속도로 10분 동안 교반하여 엑소좀을 함유한 피부주름 개선용 화장료 조성물을 제조하였다.5 parts by weight of polymersomes containing exosomes manufactured through Manufacturing Example 4 were mixed with 100 parts by weight of the effective ingredient manufactured through Manufacturing Example 3, and stirred at a speed of 150 rpm for 10 minutes to manufacture a cosmetic composition for improving skin wrinkles containing exosomes.
<실시예 2><Example 2>
상기 실시예 1과 동일하게 진행하되, 상기 제조예 4를 통해 제조된 엑소좀이 함유된 폴리머좀 0.1 중량부를 혼합하여 엑소좀을 함유한 피부주름 개선용 화장료 조성물을 제조하였다.The same procedure as in Example 1 was followed, except that 0.1 part by weight of the polymersome containing exosomes manufactured through Manufacturing Example 4 was mixed to manufacture a cosmetic composition for improving skin wrinkles containing exosomes.
<실시예 3><Example 3>
상기 실시예 1과 동일하게 진행하되, 상기 제조예 4를 통해 제조된 엑소좀이 함유된 폴리머좀 10 중량부를 혼합하여 엑소좀을 함유한 피부주름 개선용 화장료 조성물을 제조하였다.The same procedure as in Example 1 was followed, except that 10 parts by weight of the polymersomes containing exosomes manufactured through Manufacturing Example 4 were mixed to manufacture a cosmetic composition for improving skin wrinkles containing exosomes.
<비교예 1><Comparative Example 1>
글리세린 73.99g, 정제수 15mL, 카프릴릭/카프릭트라이글리세라이드 6g, 하이드로제네이티드레시틴 2g, 콜레스테롤 0.6g, 소듐하이알루로네이트 0.1g, 콜라겐 0.1g, 하이드롤라이즈드엘라스틴 0.1g을 혼합하여 유효성분을 제조하였다.The active ingredient was prepared by mixing 73.99 g of glycerin, 15 mL of purified water, 6 g of caprylic/capric triglyceride, 2 g of hydrogenated lecithin, 0.6 g of cholesterol, 0.1 g of sodium hyaluronate, 0.1 g of collagen, and 0.1 g of hydrolyzed elastin.
상기 실시예 1을 통해 제조된 폴리엘락틱엑시드(PLLA)를 이용한 피부주름 개선용 화장료 조성물의 물성을 측정하여 아래 표 1에 나타내었다.The properties of a cosmetic composition for improving skin wrinkles using polylactic acid (PLLA) manufactured through the above Example 1 were measured and are shown in Table 1 below.
<표 1><Table 1>
또한, 본 발명의 실시예 1을 통해 제조된 엑소좀을 함유한 피부주름 개선용 화장료 조성물의 피부독성을 측정하여 아래 표 3에 나타내었다.In addition, the skin toxicity of the cosmetic composition for improving skin wrinkles containing exosomes manufactured through Example 1 of the present invention was measured and shown in Table 3 below.
[단, 피부독성은 ISO 10993-5방법을 이용하였으며 아래 표 2의 기준으로 등급을 정하였으며, 생존율 70% 이상은 세포독성이 없다고 판별한다.[However, skin toxicity was determined using the ISO 10993-5 method and graded based on the criteria in Table 2 below. A survival rate of 70% or higher is determined to be non-cytotoxic.
* 세포주: Vero Cell ( African Green Monkey, KCLB No - 10081)* Cell line: Vero Cell (African Green Monkey, KCLB No - 10081)
* 사용시약: Dubelcco’s Modified Eagle’s Medium (DMEM, Sigma), Kanamycin sulfate (SAMCHUN), Sodium bicarbonate (DUKSAN), Antibiotic-Antimyotic (GenDEPOT), Fetal bovine serum (GenDEPOT)* Reagents used: Dubelcco’s Modified Eagle’s Medium (DMEM, Sigma), Kanamycin sulfate (SAMCHUN), Sodium bicarbonate (DUKSAN), Antibiotic-Antimyotic (GenDEPOT), Fetal bovine serum (GenDEPOT)
* 용매: DMEM 배지 + 10% FBS* Solvent: DMEM medium + 10% FBS
* 시험조건: 세포와 시료용출액을 24시간 동안 접촉한 후 Thiazolyl Blue Tetrazolium Bromide 시약을 처리하여 570 nm에서 흡광도를 측정* Test conditions: After contacting the cells and sample lysate for 24 hours, treat with Thiazolyl Blue Tetrazolium Bromide reagent and measure absorbance at 570 nm.
* 대조군: 음성대조군-Phosphate Buffer Saline, 양성대조군-Dimethyl sulfoxide, 용매대조군-용매* Control group: Negative control group - Phosphate Buffer Saline, Positive control group - Dimethyl sulfoxide, Solvent control group - Solvent
* 결과 표기 방법: 생존율(%)은 하기의 식을 이용해 계산하였다.* How to display results: The survival rate (%) was calculated using the following formula.
생존율(%) = {(시료처리군 OD570 / 시료 미처리군 OD570) / (시료 미 처리군 OD570 - 시료 미처리군 OD650)} × 100]Survival rate (%) = {(Sample treatment group OD570 / Sample untreated group OD570) / (Sample untreated group OD570 - Sample untreated group OD650)} × 100]
<표 2><Table 2>
<표 3><Table 3>
상기 표 3에 나타낸 것처럼, 본 발명의 실시예 1을 통해 제조된 엑소좀이 함유된 피부주름 개선용 화장료 조성물은 피부독성이 매우 낮은 것을 알 수 있다.As shown in Table 3 above, it can be seen that the cosmetic composition for improving wrinkles containing exosomes manufactured through Example 1 of the present invention has very low skin toxicity.
또한, 상기 실시예 1 내지 3 및 비교예 1을 통해 제조된 엑소좀이 함유된 피부주름 개선용 화장료 조성물의 피부주름 개선 효과 및 피부 진정 효과를 측정하여 아래 표 4에 나타내었다.In addition, the wrinkle improvement effect and skin soothing effect of the cosmetic composition for wrinkle improvement containing exosomes manufactured through Examples 1 to 3 and Comparative Example 1 were measured and shown in Table 4 below.
{단, 피부주름 개선 효과는 눈가에 주름이 발생된 30~50대 여성 50명을 대상으로 제조된 화장료 조성물을 주름이 발생된 눈가에 하루 2g씩 4주 동안 도포하도록 한 후에 개선정도를 5점 척도법으로 측정하여 평균값으로 나타내는 방법을 이용하였다.{However, the effect of improving skin wrinkles was measured using a method in which the cosmetic composition was manufactured and applied to 50 women in their 30s to 50s with wrinkles around the eyes at a dose of 2g per day for 4 weeks, and the degree of improvement was measured using a 5-point scale and expressed as the average value.
5점:매우 개선, 4점:약간 개선, 3점:개선 없음, 2점:악화, 1점:매우 악화5 points: Much improved, 4 points: Somewhat improved, 3 points: No improvement, 2 points: Worse, 1 point: Much worse
또한, 피부진정 효과는 피부발진이 발생된 10~40대 여성 피시험자 40명을 대상으로 피부발진이 발생된 부위에 제조된 화장료 조성물을 하루 2g씩 4주 동안 도포하도록 한 후에 개선정도를 5점 척도법으로 측정하여 평균값으로 나타내는 방법을 이용하였다.In addition, the skin soothing effect was measured using a method in which 40 female test subjects in their 10s to 40s with skin rashes applied 2g of the manufactured cosmetic composition to the area where the rash occurred every day for 4 weeks, and the degree of improvement was measured using a 5-point scale and expressed as the average value.
5점:매우 개선, 4점:약간 개선, 3점:개선 없음, 2점:악화, 1점:매우 악화}5 points: much improvement, 4 points: some improvement, 3 points: no improvement, 2 points: worse, 1 point: much worse}
<표 4><Table 4>
상기 표 4에 나타낸 것처럼, 본 발명의 실시예 1 내지 3을 통해 제조된 화장료 조성물은 비교예 1을 통해 제조된 화장료 조성물에 비해 우수한 피부 주름개선 및 피부진정 효과를 나타내는 것을 알 수 있다.As shown in Table 4 above, it can be seen that the cosmetic compositions manufactured through Examples 1 to 3 of the present invention exhibit superior skin wrinkle improvement and skin soothing effects compared to the cosmetic composition manufactured through Comparative Example 1.
따라서, 본 발명에 따른 엑소좀을 함유한 피부주름 개선용 화장료 조성물은 MTS공법에 적용가능하며 피부침투 효과의 향상으로 인해 우수한 피부주름 개선 효과를 나타낼 뿐만 아니라, 피부독성이 낮아 피부트러블을 유발하지 않고 피부진정 효과를 나타내는 화장료 조성물을 제공한다.Therefore, the cosmetic composition for improving skin wrinkles containing exosomes according to the present invention is applicable to the MTS method and not only exhibits an excellent skin wrinkle improvement effect due to the improvement of skin penetration effect, but also provides a cosmetic composition that does not cause skin troubles due to low skin toxicity and exhibits a skin soothing effect.
Claims (5)
상기 유효성분은 소듐하이알루로네이트, 콜라겐 및 하이드롤라이즈드엘라스틴이 함유되고,
상기 소듐하이알루로네이트, 콜라겐 및 하이드롤라이즈드엘라스틴은 120 내지 200 나노미터로 에멀전화되며.
상기 유효성분은 글리세린 100 중량부, 정제수 18 내지 22 중량부, 카프릴릭/카프릭트라이글리세라이드 7 내지 9 중량부, 병풀추출물 2.5 내지 3 중량부, 하이드로제네이티드레시틴 2.5 내지 3 중량부, 콜레스테롤 0.5 내지 1.0 중량부, 소듐하이알루로네이트 0.1 내지 0.15 중량부, 콜라겐 0.1 내지 0.15 중량부, 하이드롤라이즈드엘라스틴 0.1 내지 0.15 중량부, 폴리락틱애씨드 0.1 내지 0.15 중량부 및 인체유래 줄기세포 배양액 0.01 내지 0.02 중량부로 이루어지고,
상기 인체유래 줄기세포 배양액은 TGF(형질전환성장인자), HGF(간세포증식 인자), FGF(섬유아세포성장인자), IGF(인슐린유사성장인자), SOD(항산화효소), 콜라겐 및 파이브로넥틴으로 이루어진 그룹에서 선택된 하나 이상으로 이루어지며,
상기 엑소좀이 함유된 폴리머좀은 엑소좀과 폴리에틸렌글리콜이 5:2로 혼합된 혼합물에 팔미토일트리펩타이드를 첨가하여 제조되는 것을 특징으로 하는 엑소좀을 함유한 피부주름 개선용 화장료 조성물.
It consists of 100 parts by weight of an effective ingredient and 0.1 to 10 parts by weight of a polymersome containing exosomes.
The above effective ingredients contain sodium hyaluronate, collagen and hydrolyzed elastin.
The above sodium hyaluronate, collagen and hydrolyzed elastin are emulsified to 120 to 200 nanometers.
The above effective ingredients are composed of 100 parts by weight of glycerin, 18 to 22 parts by weight of purified water, 7 to 9 parts by weight of caprylic/capric triglyceride, 2.5 to 3 parts by weight of centella asiatica extract, 2.5 to 3 parts by weight of hydrogenated lecithin, 0.5 to 1.0 parts by weight of cholesterol, 0.1 to 0.15 parts by weight of sodium hyaluronate, 0.1 to 0.15 parts by weight of collagen, 0.1 to 0.15 parts by weight of hydrolyzed elastin, 0.1 to 0.15 parts by weight of polylactic acid, and 0.01 to 0.02 parts by weight of a human-derived stem cell culture solution.
The above human-derived stem cell culture solution is composed of at least one selected from the group consisting of TGF (transforming growth factor), HGF (hepatocyte growth factor), FGF (fibroblast growth factor), IGF (insulin-like growth factor), SOD (antioxidant enzyme), collagen, and fibronectin.
A cosmetic composition for improving skin wrinkles containing exosomes, characterized in that the polymersome containing the exosome is prepared by adding palmitoyl tripeptide to a mixture of exosomes and polyethylene glycol in a ratio of 5:2.
상기 병풀 추출물은 병풀 100 중량부에 탄소수가 1 내지 4인 저급알코올 200 내지 1000 중량부를 혼합하고 추출하여 제조되는 것을 특징으로 하는 엑소좀을 함유한 피부주름 개선용 화장료 조성물.
In claim 1,
A cosmetic composition for improving skin wrinkles containing exosomes, characterized in that the above-mentioned purslane extract is prepared by mixing 100 parts by weight of purslane and 200 to 1,000 parts by weight of lower alcohol having 1 to 4 carbon atoms and extracting the mixture.
상기 엑소좀을 함유한 피부주름 개선용 화장료 조성물은 화장수, 아이크림, 수분크림, 클렌징제품, 세럼 및 앰플로 이루어진 그룹에서 선택된 하나의 제형으로 적용되는 것을 특징으로 하는 엑소좀을 함유한 피부주름 개선용 화장료 조성물.In claim 1 or 4,
A cosmetic composition for improving skin wrinkles containing the exosome is characterized in that the cosmetic composition for improving skin wrinkles containing the exosome is applied in one formulation selected from the group consisting of a toner, an eye cream, a moisturizing cream, a cleansing product, a serum, and an ampoule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020240016510A KR102737831B1 (en) | 2024-02-02 | 2024-02-02 | Cosmetic composition for improving skin wrinkles containing exosomes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020240016510A KR102737831B1 (en) | 2024-02-02 | 2024-02-02 | Cosmetic composition for improving skin wrinkles containing exosomes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102737831B1 true KR102737831B1 (en) | 2024-12-05 |
Family
ID=93843105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020240016510A Active KR102737831B1 (en) | 2024-02-02 | 2024-02-02 | Cosmetic composition for improving skin wrinkles containing exosomes |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102737831B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120713821A (en) * | 2025-08-25 | 2025-09-30 | 山东卡森细胞治疗工程技术有限公司 | A composition containing stem cells and collagen and its application in anti-aging products |
| KR102869181B1 (en) | 2025-07-22 | 2025-10-15 | (주)지에프씨생명과학 | Composition for skin improvement and hair growth promotion containing exosomes derived from squid ink as an effective ingredient |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100564108B1 (en) | 2004-01-12 | 2006-03-24 | 주식회사 생그린 | Cosmetic composition containing a mixed plant extract having an anti-aging effect |
| KR20170003903A (en) * | 2016-12-30 | 2017-01-10 | (주)아모레퍼시픽 | Anti-aging or anti-wrinkle cosmetic composition |
| KR102224032B1 (en) | 2020-08-27 | 2021-03-08 | 주식회사 에이치앤비나인 | Active ingredient for skin anti-aging and cosmetic composition comprising the same |
| KR102553815B1 (en) * | 2022-11-30 | 2023-07-10 | 주식회사 팬터메딕 | Cosmetic composition for preventing skin aging using poly-l-lactic acid |
| KR102604529B1 (en) * | 2023-06-30 | 2023-11-23 | 박준한 | Cosmetic composition for skin improvement containing stem cell culture |
| KR102628089B1 (en) * | 2023-03-16 | 2024-01-23 | 주식회사 현대바이오랜드 | Cosmetic composition containing exosomes derived from Centella asiatica stem cell culture medium as an active ingredient and having cell regeneration and skin elastic effects |
-
2024
- 2024-02-02 KR KR1020240016510A patent/KR102737831B1/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100564108B1 (en) | 2004-01-12 | 2006-03-24 | 주식회사 생그린 | Cosmetic composition containing a mixed plant extract having an anti-aging effect |
| KR20170003903A (en) * | 2016-12-30 | 2017-01-10 | (주)아모레퍼시픽 | Anti-aging or anti-wrinkle cosmetic composition |
| KR102224032B1 (en) | 2020-08-27 | 2021-03-08 | 주식회사 에이치앤비나인 | Active ingredient for skin anti-aging and cosmetic composition comprising the same |
| KR102553815B1 (en) * | 2022-11-30 | 2023-07-10 | 주식회사 팬터메딕 | Cosmetic composition for preventing skin aging using poly-l-lactic acid |
| KR102628089B1 (en) * | 2023-03-16 | 2024-01-23 | 주식회사 현대바이오랜드 | Cosmetic composition containing exosomes derived from Centella asiatica stem cell culture medium as an active ingredient and having cell regeneration and skin elastic effects |
| KR102604529B1 (en) * | 2023-06-30 | 2023-11-23 | 박준한 | Cosmetic composition for skin improvement containing stem cell culture |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102869181B1 (en) | 2025-07-22 | 2025-10-15 | (주)지에프씨생명과학 | Composition for skin improvement and hair growth promotion containing exosomes derived from squid ink as an effective ingredient |
| CN120713821A (en) * | 2025-08-25 | 2025-09-30 | 山东卡森细胞治疗工程技术有限公司 | A composition containing stem cells and collagen and its application in anti-aging products |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112891241B (en) | Targeted mitochondrial skin anti-aging nano composition and preparation method and application thereof | |
| JP5735965B2 (en) | Injectable composition combining filler and fibroblast growth medium | |
| KR101678621B1 (en) | Composition comprising spicules for skin care | |
| KR102737831B1 (en) | Cosmetic composition for improving skin wrinkles containing exosomes | |
| CN110237022A (en) | A kind of freeze-dried powder, solvent and its application | |
| CN103619415A (en) | Exopolysaccharide for the treatment and/or care of the skin, mucous membranes, hair and/or nails | |
| KR102613845B1 (en) | Cosmetic composition for improvement of skin derived from natural products | |
| CN113301910A (en) | Skin rejuvenation and healing mixtures of peptide components and uses thereof | |
| Tansathien et al. | Development of sponge microspicule cream as a transdermal delivery system for protein and growth factors from deer antler velvet extract | |
| KR102582633B1 (en) | Cosmetic composition for skin regeneration and wrinkle improvement containing epidermal growth factor liposomes and growth factor complex | |
| KR20150128481A (en) | Composition for application of skin comprising of extracellular matrix and thermo sensitive macromolecule | |
| WO2017105413A1 (en) | Stem cell stimulating compositions and methods of treating melasma | |
| WO2013050959A1 (en) | Composition for the treatment of skin lesions | |
| RU2383341C2 (en) | Method of skin rejuvenation | |
| KR101965396B1 (en) | Agent for treating skin aging | |
| KR20210075051A (en) | Composition for for treating wound or scar comprising hydrogel patches | |
| US20200164037A1 (en) | Dermocosmetic composition containing synthetic platelet-like molecules to treat skin aging and stimulate hair growth | |
| KR20100096447A (en) | Cosmetic composition comprising matrials cultured adult stem cells derived from swine placenta tissue and proteins extracted therefrom | |
| KR102553815B1 (en) | Cosmetic composition for preventing skin aging using poly-l-lactic acid | |
| JP2022523046A (en) | Cosmetic / dermatological composition | |
| KR102785777B1 (en) | Preparation method of nanoparticles containing ceramide, physiologically active materials and cosmetic composition comprising the same | |
| KR101446706B1 (en) | Composition for skin rejuvenation comprising FGF | |
| AU2024282154A1 (en) | Cell-free lipoaspirate-derived preparation, compositions comprising the preparation and uses thereof | |
| KR101917026B1 (en) | Cosmetic composition for skin wrinkle improvement and prevention | |
| WO2016197144A1 (en) | Cordyceps containing topical skin care formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20240202 |
|
| PA0201 | Request for examination |
Patent event code: PA02011R01I Patent event date: 20240202 Comment text: Patent Application |
|
| PA0302 | Request for accelerated examination |
Patent event date: 20240214 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination |
|
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240528 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20241123 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20241129 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20241129 End annual number: 10 Start annual number: 1 |
|
| PG1601 | Publication of registration |